medigraphic.com

2022, Number 2

<< Back Next >>

Enf Infec Microbiol 2022; 42 (2)

IgG anti-SARS-COV-2 antibodies and their correlation with clinical signs and symptoms in Northern Mexico

Sánchez GJM; Portillo GJH, Ishida GC, Rivera CAE, Franco SR

Language: Spanish
References: 30
Page: 54-60
PDF size: 296.76 Kb.


ABSTRACT

During the SARS-COV-2 pandemic, it has been necessary to have precise, exact and applicable diagnostic tests for the early detection of infections, and to favor isolation measures and timely management. These tests must be used, applied and interpreted by qualified health personnel. Material and methods. We analyzed the semi-quantitative determination of the positive index (≥ 1.4) of IgG antibodies against the nucleocapsid of the SARS-COV-2 virus by immunoassay, during the months of November 2020 to February 2021, and its association with signs and symptoms, expressed by each of the participants. Results. 318 patients, adults between 17 and 80 years of age, both sexes (51% women, 49% men) were included. The positive level percentage of the igg index was: November 50.89%, December 76.14%, January 62.2% and February 52% of cases. November was the month with the highest percentage of cases associated with contact with patients and the presence of headache, even with a lower percentage of positivity. No statistically significant association was found between the positive index and symptoms (p ›0.05). Discussion. Despite not finding a statistical association, it is possible to infer that the variable, contact with patients, is related to at least one third of people with a positive index, followed by practically two out of 10 with headache and general malaise, fever was the least frequent symptom associated with positivity.


REFERENCES

  1. Masson, G., Vaidya, A. y Bean, M., “The coronavirusplaybook: how 12 health systems are respondingto the pandemic”. Disponible en: https://www.beckershopspitalreviw.com/infection-control/the-coronavirus-playbook-how-12-health-systems-are-responding-to-the-pandemic.html. Fecha de acceso: 2 deseptiembre de 2021.

  2. Staff Reporter, “fda creates new pathway for emergencyuse authorization of sars-cov-2 serology tests. Disponibleen: https://360dx.com/regulatory-news-fda-approvals/fda-creates-new-pathway-emergency-use-authorization-sars-cov-2?utm 5. Fecha de acceso: 3 de septiembrede 2021.

  3. Suhandynata, R.T., Bevins, N.J., Tran, J.T., Huang, D., Hoffman,M.A., Lund, K. et al., “sars-cov-2 serology statusdetected by commercialized platforms distinguishesprevious infection and vaccination adaptive immuneresponses”. Disponible en: https://www.medrxiv.org/content/10.1101/2021.03.10.21253299v1. doi: https://doi.org/10.1101/2021.03.10.21253299. Fecha de acceso:3 de septiembre de 2021.

  4. paho, “Directices de laboratorio para la detección y eldiagnóstico de la infección con el virus covid-19”, 30 demarzo de 2020.

  5. Murray, S., “covid-19 finnally an elisa emerges. Contagionlive, 18 de abril de 2020.

  6. ops, “Interpretation of laboratory results for covid-19diagnosis”, 6 de mayo de 2020.

  7. Instituto de Salud Carlos III, “Guía para la utilización detests rápidos de anticuerpos para covid-19”, Gobiernode España, 6 de abril de 2020.

  8. McDade, T.W., Demonbreun, A.R., Sancilio, A., Mustanski,B., D’Aquila, R.T. y McNally, E.M., “Durabilityof antibody response to vaccination and surrogateneutralization of emerging variants based on sars-cov-2exposure history”, Scientific Reports, 2021, 11:17325.Disponible en: https://doi.org/10.1038/s41598-021-

  9. 96879-3. Fecha de acceso: 16 de septiembre de 2021.9. Pedersen, A., “fda warns of covid-19 antibody testinglimitations”. Disponible en: https://www-mddionline.com/fda-warns-covid-19-antibody-testing-limitations.

  10. Staff Reporter, “fda working with nci, niaid on sars-cov-2serology test validation effort. Disponible en: https://www.360dx.com/molecular-diagnostics/fda-workingnci-niaid-sars-cov-2-serology-test-validation-effort?utm_source=Sailthru&utm_médium=em.

  11. Mateus, J., Dan, J.M., Zhang, Z., Rydyznski Moderbacher,C., Lammers, M., Goodwin, B., Sette, A. et al.,“Low-dose mrna-1273 covid-19 vaccine generates durablememory enhanced by cross-reactive t cells”, Science,2021. Disponible en: https://www.science.org/doi/epdf/10.1126/science.abj9853. Fecha de acceso: 16 deseptiembre de 2021.

  12. Saily, D., “Can consumers collect their own biologicalspecimens for direct-yo-consumer sars-cov-2 tests? fdaSays “No” to clinical labs announcing such tests. Disponibleen: https://www.darkdaily.com.

  13. Perera, R.A., Mok, C.K., Tsang, O.T., Li, H., Ko, R.L.,Wu, N.C. et al., “Serological assays for severe acuterespiratory syndrome coronavirus 2 (sars-cov-2), March2020”, Euro Surveill, 2020, 25 (16): 2000421. doi:10.2807/15607917.ES.2020.25.16.2000421.

  14. Evaluation of the abbott sars-cov-2 igg for the detectionof anti-sars-cov-2 antibodies. Disponible en: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/890566/Evaluation_of_Abbott_SARS_CoV_2_IgG_PHE.pdf.

  15. cdc, “Interim guidelines for covid-19 antibody testing inclinical and public health settings. Disponible en: https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antibody-tests-guidelines.html.

  16. “Inmunoensayo del sars-cov-2. Abbott Core Laboratory”.Disponible en: https://www.corelaboratory.abbott/int/es/offerings/segments/infectious-disease/sars-cov-2-.

  17. Sethuraman, N., Stanleyraj Jeremiah, S. y Ryo, A., “Interpretingdiagnostic tests for sars-cov-2. Opinion”, jama, 6de mayo de 2020. Disponible en: https://jamanetwork.com/.18. Ni, L., Ye, F., Cheng, M.L., Feng, Y., Deng,

  18. Y.Q., Zhao, H. et al., “Detection of sars-cov-2 specifichumoral and cellular immunity in covid-19 convalescentindividuals”, Immunity, 2020, 52 (6): 971-977. e3. doi:10.1016/j.immuni.2020.04.023.

  19. Ou, X., Liu, Y., Lei, X., Li, P., Mi, D., Ren, L. et al., “Characterizationof spike glycoprotein of sars-cov-2 on virusentry and its immune cross-reactivity with sars-cov-2”,Nat Commun, 2020, 11 (1): 1620. doi:10.1038/s41467-020-15562-9.

  20. Grifoni, A., Weiskopf, D., Ramírez, S.I., Mateus, J., Dan,J.M., Moderbacher, C.R. et al., “Targets of t cell responsesto sars-cov-2 coronavirus in humans with covid-19disease and unexposed individuals”, Cell, 2020, 181 (7):1489-1501.e15. doi: 10.1016/j.cell.2020.05.01.

  21. Pollán, M., Pérez-Gómez, B., Pastor-Barriuso, R., Oteo, J.,Hernán, M.A., Pérez-Olmeda, M. et al., “ene-covid StudyGroup. Prevalence of sars-cov-2 in Spain (ene-covid): a nationwide,population-based seroepidemiological study”,The Lancet, 2020. doi:10.1016/S0140-6736(20)31483-5.

  22. Bryan, A., Pepper, G., Wener, M.H., Fink, S.L., Morishima,C., Chaudhary, A. et al., “Performance characteristicsof the Abbott Architect sars-cov-2 igg assay andseroprevalence in Boise, Idaho”, J Clin Micro-biol, 2020,58 (8): e00941-20. doi: 10.1128/JCM.00941-20.

  23. Walls, A.C., Park, Y.J., Tortorici, M.A., Wall, A., McGuire,A.T. y Veesler, D., “Structure, function, and antigenicityof the sars-cov-2 spike glycoprotein”, Cell, 2020, 181 (2):281-292.e6. doi: 10.1016/j.cell.2020.02.058.

  24. Amanat, F., Nguyen, T., Chromikova, V., Strohmeier, S.,Stadlbauer, D., Kaijun Jiang, A.J. et al., “A serological assayto detect sars-cov-2 seroconversion in humans”, 2020.doi: https://doi.org/10.1101/ 2020.03.17.20037713.

  25. Callaway, E., “Coronavirus vaccines: five key questionsas trials begin”, Nature, 2020, 579. doi: 10.1038/d41586-020-00798-8.

  26. https://www.paho.org/es/noticias/4-1-2021-mexico-ha-sido-primer-pais-region-incorporar-pruebas-rapidas-deteccion-antigenos.

  27. Rodeles, L.M., Peverengo, L.M., Benítez, R., Benzaquen,N., Serravalle, P., Long, A.K., Ferreira, V., Benítez,A.D., Zunino, L., Lizárraga, C. y Vicco, M.H., “Seroprevalenceof anti-sars-cov-2 igg in asymptomatic andpauci-symptomatic people over a 5 month survey inArgentina”, Rev Panam Salud Publica, 2021, 45: e66.doi: 10.26633/RPSP.2021.66. PMID: 34168682; PMCID:PMC8216497.

  28. Kontou, P.I., Braliou, G.G., Dimou, N.L., Nikolopoulos,G. y Bagos, P.G., “Antibody tests in detecting sars-cov-2infection: a meta-analysis”, Diagnostics, 2020, 10 (5):319. Disponible en: https://doi.org/10.3390/diagnostics1005031.

  29. Benotmane, I., Gautier, G., Perrin, P. et al., “Antibodyresponse after a third dose of the mrna-1273 sars-cov-2vaccine in kidney transplant recipients with minimal serologicresponse to 2 doses”, jama, 23 de julio de 2021.doi: 10.1001/jama.2021.12339

  30. Planas, D., Veyer, D., Baidaliuk, A. et al., “Reducedsensitivity of sars-cov-2 variant delta to antibody neutralization”,Nature, 2021, 596: 276-280. Disponible en:https://doi.org/10.1038/s41586-021-03777-9.




2020     |     www.medigraphic.com